Concepedia

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

Tae Hyung Han, R. Chen, Ranjana H. Advani, R.B. Berryman, Scott E. Smith, Andres Forero‐Torres, Joseph D. Rosenblatt, Mitchell R. Smith, Jasmine Zain, Naomi Hunder,

Cancer Chemotherapy and Pharmacology · 2013 · 15 citations · 7 references

DOIFull text

Open access

Concepts

References

7

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 979 citations · Full text

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 907 citations

International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

PubMed · 2005 · 316 citations

, , +20